Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kodiak Sciences Inc.

Get SEC filing alerts via email and in your feed for Kodiak Sciences Inc.

KOD

Kodiak Sciences Inc.

About Kodiak Sciences Inc.

Kodiak Sciences Inc. develops innovative retinal therapies using its Antibody Biopolymer Conjugate (ABC) Platform. Its core focus is on creating biologics for major retinal diseases like AMD, diabetic retinopathy, and retinal vein occlusion. The company’s key products include tarcocimab, KSI-501, and KSI-101, targeting inflammation and vascular issues. Kodiak emphasizes high efficacy, durability, and tailored delivery, aiming to improve patient outcomes and reduce treatment burdens in ophthalmology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kodiak Sciences Inc.

1
1
Kodiak Sciences Inc. Kodiak Sciences Reports $58.2 Million Net Loss in Q1 2026 Amid Increased R&D Spending

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Kodiak Sciences Inc. Kodiak Sciences Reports $229.97 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Kodiak Sciences Inc. Kodiak Sciences Reports $61.5 Million Net Loss and Significant Cash Decline in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kodiak Sciences Inc. Kodiak Sciences Reports $54.3 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kodiak Sciences Inc. Kodiak Sciences Reports $57.5 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Kodiak Sciences Inc. Kodiak Sciences Reports $176.2 Million Net Loss for 2024, Decreased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Kodiak Sciences Inc. Kodiak Sciences Reports Financial Results, Advances Clinical Programs for Retinal Diseases

Via official filing (AI summary) | over 1 year ago | 0 comments